Ferring Product Development China, Global R&D life cycle management department, Ferring Pharmaceuticals (Asia) Company Limited, Beijing, China.
Global R&D Life Cycle Management Department, Ferring International Center SA, St-Prex, Switzerland.
Expert Opin Drug Deliv. 2022 Oct;19(10):1247-1264. doi: 10.1080/17425247.2022.2105317. Epub 2022 Aug 9.
Long-acting Injectable PLGA microspheres have gained more and more interest and attention in the field of life cycle management of pharmaceutical products due to their biocompatibility and biodegradability. So far, a multitude of trial-and-error experiments at lab scale have been used for establishing the correlation relationship between critical process parameters, critical material attributes and critical quality attributes. However, few published studies have elaborated on the development of PLGA microspheres from an industrial perspective.
In this review, the scale-up feasibility of translational technologies of PLGA microspheres manufacturing has been evaluated. Additionally, state-of-the-art of technologies and facilities in PLGA development have been summarized. Meanwhile, the industrial knowledge matrix of PLGA microspheres development and research is establishing which provides comprehensive insight for understanding properties of PLGA microspheres as controlled/sustained release vehicle.
There is still big gap between fundamental research in academic institute and product development in pharmaceuticals. Therefore, the difference and connection between them should be identified gradually for better understanding of PLGA microspheres development.
由于具有生物相容性和可生物降解性,长效注射用 PLGA 微球在药物产品生命周期管理领域引起了越来越多的关注和重视。到目前为止,已经进行了大量的实验室规模的反复试验,以建立关键工艺参数、关键材料属性和关键质量属性之间的相关性。然而,很少有发表的研究从工业角度详细阐述 PLGA 微球的开发。
在这篇综述中,评估了 PLGA 微球制造转化技术的放大可行性。此外,还总结了 PLGA 开发的最新技术和设备。同时,正在建立 PLGA 微球开发和研究的工业知识库,为理解作为控制/缓释载体的 PLGA 微球的特性提供全面的见解。
学术界的基础研究和制药产品的开发之间仍然存在很大的差距。因此,应该逐渐确定它们之间的差异和联系,以便更好地理解 PLGA 微球的开发。